托伐普坦治疗儿童及青少年常染色体显性多囊肾病:随机对照试验
这项在20个学术儿科肾脏病中心开展的3b期两部分试验的1年随机双盲部分,评估托伐普坦在儿童及青少年常染色体显性多囊肾病(ADPKD)中的安全性和有效性。共随机91例(1组66例,2组25例),托伐普坦组第1周尿渗透压和比重降低幅度均大于安慰剂组(P<0.001),1组12个月身高调整总肾脏体积增加托伐普坦组2.6% vs 安慰剂组5.8%(P>0.05)。托伐普坦显示药效学活性,水样不良反应可控,停药少。
要点
- 托伐普坦组第1周尿渗透压降低390 mOsm/kg,安慰剂组降低90 mOsm/kg(P<0.001)。
- 1组12个月身高调整总肾脏体积增加托伐普坦组2.6% vs 安慰剂组5.8%(P>0.05)。
- 水样不良反应发生率托伐普坦组65% vs 安慰剂组16%,高钠血症2% vs 0%。
核心结论
- 托伐普坦在儿童ADPKD中表现出药效学活性;水样不良反应可控,停药例数少。
研究设计与样本
- 3b期两部分试验的1年随机双盲部分,在20个学术儿科肾脏病中心开展。
- 关键入选标准为ADPKD且eGFR≥60 ml/min per 1.73 m2。
- 12-17岁为目标组(1组,入组目标n≥60);4-11岁可额外入组(2组,预计约40例)。
- 治疗为托伐普坦或安慰剂,按体重和耐受性滴定。
- 共同主要终点为第1周晨尿渗透压和比重相对基线的变化;关键次要终点为1组12个月身高调整总肾脏体积(htTKV)变化。
主要发现
- 共随机91例(1组66例,2组25例)。
- 第1周晨尿渗透压最小二乘均值降低:托伐普坦组-390(28)mOsm/kg vs 安慰剂组-90(29)mOsm/kg(P<0.001)。
- 第1周比重最小二乘均值降低:托伐普坦组-0.009(0.001) vs 安慰剂组-0.002(0.001)(P<0.001)。
- 1组12个月htTKV增加:托伐普坦组2.6% vs 安慰剂组5.8%(P>0.05)。
- 水样不良反应发生率托伐普坦组65% vs 安慰剂组16%;高钠血症发生率托伐普坦组2% vs 安慰剂组0%。
临床怎么用
- 原文未据此给出推荐。
局限性
- 统计比较为探索性及事后分析。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Tolvaptan slows expansion of kidney volume and kidney function decline in adults with autosomal dominant polycystic kidney disease (ADPKD). Progression during childhood could be treated before irreversible kidney damage occurs, but trial data are lacking. We evaluated the safety and efficacy of tolvaptan in children/adolescents with ADPKD. METHODS: This was the 1-year, randomized, double-blind, portion of a phase 3b, two-part trial being conducted at 20 academic pediatric nephrology centers. Key eligibility criteria were ADPKD and eGFR ≥60 ml/min per 1.73 m2. Participants aged 12-17 years were the target group (group 1, enrollment goal n≥60); participants aged 4-11 years could additionally enroll (group 2, anticipated enrollment approximately 40). Treatments were tolvaptan or placebo titrated by body weight and tolerability. Coprimary end points, change from baseline in spot urine osmolality and specific gravity at week 1, assessed inhibition of antidiuretic hormone activity. The key secondary end point was change in height-adjusted total kidney volume (htTKV) to month 12 in group 1. Additional end points were safety/tolerability and quality of life. Statistical comparisons were exploratory and post hoc. RESULTS: Among the 91 randomized (group 1, n=66; group 2, n=25), least squares (LS) mean reduction (±SEM) in spot urine osmolality at week 1 was greater with tolvaptan (-390 [28] mOsm/kg) than placebo (-90 [29] mOsm/kg; P<0.001), as was LS mean reduction in specific gravity (-0.009 [0.001] versus -0.002 [0.001]; P<0.001). In group 1, the 12-month htTKV increase was 2.6% with tolvaptan and 5.8% with placebo (P>0.05). For tolvaptan and placebo, respectively, 65% and 16% of subjects experienced aquaretic adverse events, and 2% and 0% experienced hypernatremia. There were no elevated transaminases or drug-induced liver injuries. Four participants discontinued tolvaptan, and three discontinued placebo. Quality-of-life assessments remained stable. CONCLUSIONS: Tolvaptan exhibited pharmacodynamic activity in pediatric ADPKD. Aquaretic effects were manageable, with few discontinuations. CLINICAL TRIAL REGISTRY NAME AND REGISTRATION NUMBER: Safety, Pharmacokinetics, Tolerability and Efficacy of Tolvaptan in Children and Adolescents With ADPKD (Autosomal Dominant Polycystic Kidney Disease) NCT02964273.
引用
- Mekahli D, Guay-Woodford LM, Cadnapaphornchai MA, et al. Tolvaptan for Children and Adolescents with Autosomal Dominant Polycystic Kidney Disease: Randomized Controlled Trial. Clin J Am Soc Nephrol. 2023. PMID: 36719158. doi:10.2215/CJN.0000000000000022
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。